<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>巴利昔单抗 &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/balixidankang/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Thu, 05 Sep 2019 03:04:47 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>巴利昔单抗 &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2019-2023年中国巴利昔单抗市场研究报告</title>
		<link>https://www.yuanzhezixun.com/2019-2023nianzhongguobalixidankangshichangyanjiubaogao/</link>
		
		<dc:creator><![CDATA[chrislee]]></dc:creator>
		<pubDate>Thu, 05 Sep 2019 03:04:47 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[巴利昔单抗]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=21346</guid>

					<description><![CDATA[截止2019年8月，中国具有器官移植资质的医院178家。其中具有肝脏移植资质医院97家，肾脏移植医院136家，心脏移植医院46家，肺脏移植医院32家，胰腺和小肠移植医院43家。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
